DMRA
Damora Therapeutics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.56B
P/E Ratio
—
EPS
$-4.08
Beta
1.51
52W High
$38.33
52W Low
$2.45
50-Day MA
$26.06
200-Day MA
$17.23
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company is headquartered in Copenhagen, Denmark.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-36.54M |
| Operating Margin | 0.00% |
| Return on Equity | -163.80% |
| Return on Assets | -16.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-110.11 |
| Price-to-Book | 163.79 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.46 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $60.30M |
| Float | $43.75M |
| % Insiders | 7.85% |
| % Institutions | 8.14% |
Historical Volatility
HV 10-Day
57.04%
HV 20-Day
48.68%
HV 30-Day
82.21%
HV 60-Day
103.65%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($45.17 target)
5
BuyMore HEALTHCARE Stocks
Data last updated: 5/5/2026